Jaguar Health (NASDAQ:JAGX) Lifted to “Hold” at StockNews.com

Jaguar Health (NASDAQ:JAGX) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Wednesday.

Jaguar Health Trading Up 1.0 %

NASDAQ:JAGX opened at $4.09 on Wednesday. Jaguar Health has a 52-week low of $3.07 and a 52-week high of $41.76. The stock has a fifty day moving average of $7.16 and a 200 day moving average of $6.78. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.89 and a quick ratio of 1.39.

Jaguar Health (NASDAQ:JAGX) last posted its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($3.60) earnings per share (EPS) for the quarter. The business had revenue of $2.35 million for the quarter. Jaguar Health had a negative net margin of 377.95% and a negative return on equity of 642.15%. On average, equities analysts forecast that Jaguar Health will post -5.42 EPS for the current fiscal year.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.